Cormorant Asset Management Has Lifted Portola Pharmaceuticals (PTLA) Position By $16.80 Million; Last Week GlaxoSmithKline plc (LON:GSK) Coverage

December 16, 2017 - By Vivian Currie

Cormorant Asset Management Llc increased Portola Pharmaceuticals Inc (PTLA) stake by 50% reported in 2017Q2 SEC filing. Cormorant Asset Management Llc acquired 300,000 shares as Portola Pharmaceuticals Inc (PTLA)’s stock rose 22.73%. The Cormorant Asset Management Llc holds 900,000 shares with $50.55M value, up from 600,000 last quarter. Portola Pharmaceuticals Inc now has $3.07B valuation. The stock decreased 1.11% or $0.53 during the last trading session, reaching $47.02. About 1.67 million shares traded or 106.81% up from the average. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since December 16, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.

Among 28 analysts covering GlaxoSmithKline PLC (LON:GSK), 8 have Buy rating, 4 Sell and 16 Hold. Therefore 29% are positive. GlaxoSmithKline PLC had 416 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, September 30 by BNP Paribas. Kepler Cheuvreux maintained GlaxoSmithKline plc (LON:GSK) rating on Thursday, July 27. Kepler Cheuvreux has “Reduce” rating and GBX 1520 target. Deutsche Bank maintained GlaxoSmithKline plc (LON:GSK) on Thursday, October 27 with “Hold” rating. The firm has “Neutral” rating given on Monday, June 27 by Credit Suisse. The stock of GlaxoSmithKline plc (LON:GSK) has “Neutral” rating given on Thursday, July 13 by JP Morgan. The firm earned “Buy” rating on Monday, October 17 by Bryan Garnier & Cie. BNP Paribas maintained it with “Neutral” rating and GBX 1400 target in Monday, December 7 report. The firm has “Hold” rating given on Tuesday, May 23 by Deutsche Bank. The firm earned “Hold” rating on Friday, August 19 by Cantor Fitzgerald. The firm earned “Neutral” rating on Friday, August 21 by Bryan Garnier & Cie. See GlaxoSmithKline plc (LON:GSK) latest ratings:

13/12/2017 Broker: Berenberg Rating: Buy Old Target: GBX 1760.00 New Target: GBX 1760.00 Maintain
13/12/2017 Broker: JP Morgan Rating: Neutral Maintain
13/12/2017 Broker: Citigroup Rating: Neutral New Target: GBX 1400.00 Maintain
30/11/2017 Broker: Shore Capital Rating: Hold Maintain
30/11/2017 Broker: JP Morgan Rating: Neutral Maintain
27/11/2017 Broker: UBS Rating: Buy Old Target: GBX 1550.00 New Target: GBX 1550.00 Upgrade
22/11/2017 Broker: Shore Capital Rating: Hold Maintain
22/11/2017 Broker: HSBC Rating: Buy Old Target: GBX 1925.00 New Target: GBX 1925.00 Maintain
16/11/2017 Broker: Jefferies Rating: Buy Old Target: GBX 1540.00 New Target: GBX 1450.00 Maintain
09/11/2017 Broker: Societe Generale Rating: Sell New Target: GBX 1075.00 Maintain

The stock increased 0.35% or GBX 4.5 during the last trading session, reaching GBX 1295. About 15.05M shares traded or 42.63% up from the average. GlaxoSmithKline plc (LON:GSK) has 0.00% since December 16, 2016 and is . It has underperformed by 16.70% the S&P500.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company has market cap of 62.88 billion GBP. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It has a 27.38 P/E ratio. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

Investors sentiment increased to 2.16 in 2017 Q2. Its up 0.85, from 1.31 in 2017Q1. It is positive, as 17 investors sold PTLA shares while 58 reduced holdings. 45 funds opened positions while 53 raised stakes. 48.64 million shares or 0.79% more from 48.26 million shares in 2017Q1 were reported. Art Lc stated it has 57,500 shares. Qs Invsts Ltd Co owns 2,611 shares. Amalgamated State Bank accumulated 0.01% or 6,376 shares. First Mercantile Tru holds 7,500 shares or 0.08% of its portfolio. One Trading Limited Partnership reported 64,173 shares. Captrust Financial Advisors reported 0% stake. Arrowstreet Ltd Partnership holds 0.01% or 35,300 shares in its portfolio. C Gp Hldg A S reported 0.08% stake. Profund Advsr Llc, Maryland-based fund reported 23,074 shares. Paradigm Asset Ltd Liability invested in 11,800 shares. Prelude Cap Mngmt Limited Liability Com holds 247 shares or 0% of its portfolio. Wells Fargo And Co Mn, a California-based fund reported 41,783 shares. Pictet Asset Mngmt Ltd holds 522,237 shares. Next Financial Inc reported 100 shares. Martingale Asset Management Lp reported 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Portola Pharmaceuticals had 30 analyst reports since August 5, 2015 according to SRatingsIntel. Goldman Sachs downgraded Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) on Monday, March 28 to “Neutral” rating. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Outperform” rating given on Friday, February 24 by Oppenheimer. Oppenheimer maintained the stock with “Buy” rating in Monday, June 26 report. The stock has “Buy” rating by Morgan Stanley on Monday, June 26. Oppenheimer maintained the stock with “Buy” rating in Sunday, July 23 report. On Wednesday, September 20 the stock rating was maintained by Credit Suisse with “Buy”. Credit Suisse maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Thursday, August 10. Credit Suisse has “Hold” rating and $7000 target. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Outperform” rating by Credit Suisse on Monday, March 28. The rating was maintained by Citigroup on Monday, June 26 with “Buy”. On Friday, August 19 the stock rating was maintained by Credit Suisse with “Neutral”.

Cormorant Asset Management Llc decreased Nevro Corp stake by 80,000 shares to 270,000 valued at $20.10M in 2017Q2. It also reduced Myokardia Inc stake by 130,000 shares and now owns 1.00M shares. Protagonist Therapeutics Inc was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com